anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Autoimmune polyglandular syndrome (APS) comprises a complex association of autoimmune pathological conditions. APS Type 1 originates from loss-of-function mutations in the autoimmune regulator (AIRE) gene. APS2, APS3 and APS4 are linked to specific HLA alleles within the major histocompatibility complex, with single-nucleotide polymorphisms (SNPs) in non-HLA genes also contributing to disease. In general, variability in the AIRE locus and the presence of heterozygous loss-of-function mutations can impact self-antigen presentation in the thymus. In this study, whole-exome sequencing (WES) was performed on a sixteen-year-old female APS3A/B patient to investigate the genetic basis of her complex phenotype. The analysis identified two variants (p.Arg111Trp and p.Thr101Ile) of the hepatitis A virus cell receptor 2 gene (HAVCR2) encoding for the TIM-3 (T cell immunoglobulin and mucin domain 3) protein. These variants were predicted, through in silico analysis, to impact protein structure and stability, potentially influencing the patient's autoimmune phenotype. While confocal microscopy analysis revealed no alteration in TIM-3 fluorescence intensity between the PBMCs isolated from the patient and those of a healthy donor, RT-qPCR showed reduced TIM-3 expression in the patient's unfractionated PBMCs. A screening conducted on a cohort of thirty APS patients indicated that the p.Thr101Ile and p.Arg111Trp mutations were unique to the proband. This study opens the pathway for the search of TIM-3 variants possibly linked to complex autoimmune phenotypes, highlighting the potential of novel variant discovery in contributing to APS classification and diagnosis.
A single blood specimen (85ml) will be drawn. They will be asked to empty their bladder. The patch will be applied. Following application of the patch, heart rate and blood pressure will be measured every 15 minutes for the 1st hour, every 30 minutes for the next 3 hours and hourly after that until the end of the study. Urine will be collected in two 4-hour aliquots. FMD will be measured after approximately 6 hours of nicotine exposure. After 8 hours exposure, following the end of the 2nd urine collection, the patch will be removed and the subject discharged. Following a minimum of 2 weeks (maximum 8 weeks) washout, the subject will repeat the study, receiving the other patch.
Participants will all have history of good to excellent clinical response to intranasal ketamine for at least two months and on a treatment schedule varying from use every other day to every fifth day. Participants will be tested one or two days beyond their customary administration date and again 2-3 hours after their administration of ketamine.
The present disclosure detects lesions in different datasets using a semi-supervised domain adaptation manner with very few labeled target samples. Conventional approaches suffer due to domain-gap between source and target domain. Initially, the system receives an input image, and extracts a plurality of multi-scale feature maps from the input image. Further, a classification map is generated based on the plurality of multi-scale feature maps. Further, a 4D vector corresponding to each of a plurality of foreground pixels is computed. Further, an objectness score corresponding the plurality of foreground pixels is computed. After computing the objectness score, a centerness score is computed for each of the plurality of foreground pixels using a single centerness network. Further, an updated objectness score is computed for each of the plurality of foreground. Finally, a plurality of multi-sized lesions in the input image are detected using a trained few-shot adversarial lesion detector network.
An educational interview by trained nurses was performed at three months in patients allocated to the intervention group. The visit was carried out at the hospital. Family and caregivers were also asked to attend this visit for instruction. For patients unable to move, the nursing team went to their home to perform the intervention, or it was conducted by phone. The duration of this interview was approximately 40 minutes and was focused on some measures and recommendations to improve or maintain adherence. Then, there is a reminder call at 6 months.
Clinical studies of ribavirin/INTRON A therapy did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects.

Ribavirin is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients often have decreased renal function, care should be taken in dose selection. Renal function should be monitored and dosage adjustments should be made accordingly. Ribavirin should not be used in patients with creatinine clearance <50 mL/min. (See WARNINGS).

In general, ribavirin capsules should be administered to elderly patients cautiously, starting at the lower end of the dosing range, reflecting the greater frequency of decreased hepatic and/or cardiac function, and of concomitant disease or other drug therapy. In clinical trials, elderly subjects had a higher frequency of anemia (67%) than did younger patients (28%) (See WARNINGS).
All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL.
PURPOSE:To provide a blood pressure-regulating drug, containing a trithiazole pentamethine cyanine compound as an active component, almost free from toxicity and side effect, and exhibiting excellent hypotensive action by oral administration. CONSTITUTION:The titled drug can be prepared by using the compound of formula (X is halogen, perchlorate residue, nitrate residue or organic acid residue) as an active component. It has been newly found that the compound of formula exhibits ideal pressure-regulating action characterized by the long-acting hypotensive activity against hypertension and the lack of action to a healthy person, and is effective as blood pressure-regulating agent. It is free from the side effects of the conventional drug for hypertension, e.g. orthostatic hypotension, bradycardia, etc., and can be applied continuously over a long period. It exhibits drug action at a dose of only 10-500mug per dose. Above all, the compound of formula wherein X=I is preferable. The drug is suitable as a remedy for malignant hypertension, essential hypertension, renal hypertension, etc.
PROBLEM TO BE SOLVED: To provide an image reading report preparation device automatically extracting candidates of a fixed phrase and being capable of reducing time required to select the fixed phrase.SOLUTION: An image reading report preparation support device 10 comprises: a storage section 11; an analysis section 12; a fixed phrase identification section 13; and a report preparation section 14. The storage section 11 stores identification information including image acquisition information when a medical image is acquired, fixed phrase information including a fixed phrase for preparing an image reading report and association information where the identification information and the fixed phrase are associated with each other beforehand. The analysis section 12 analyzes the medical image. The identification information includes analysis classes by the analysis section 12. The fixed phrase identification section 13 identifies the fixed phrase associated with the identification information in the medical image on the basis of the association information. The report preparation section 14 prepares the image reading report by replacing information of a replaceable portion with information of analysis results acquired by the analysis section 12 with a predetermined portion out of the fixed phrase identified as the replaceable portion.SELECTED DRAWING: Figure 1
This lung cancer cohort will retrospectively identify and enroll the participants with centrally located primary NSCLC receiving bronchial sleeve resection with or without pulmonary artery angioplasty in minimally invasive approaches (RATS or VATS) between January 2015 and September 2024 from the institutional databases. The choice of minimally invasive surgical approaches depends on the willingness of the surgeons and the participants in this study.
Doxorubicin 60 mg/m² iv bolus every 3 weeks. Treatment is continued for a maximum of 6 cycles or until unacceptable toxicity, progressive disease or patient withdrawal.
A therapeutic preparation for topical treatment of trichomonas vaginalis vaginitis, comprises say 1/4 to 1 1/2 per cent 2-amino-5-nitrothiazole or 2-acylamino-5-nitrothiazole, the acyl group having up to 12 carbon atoms e.g. acetyl, propionyl, butyryl, caproyl, lauroyl, distributed in a vehicle which is semiliquid at body temperature; the vehicle may be a gelatinous or water-dispersible colloid or a cream-like aqueous oleaginous emulsion, or in the form of a suppositary.  The preferred vehicle is a viscous aqueous gel comprising one or more cellulose derivatives e.g. methyl, hydroxy-ethyl, sodium carboxymethyl cellulose; acacia, tragacanth, bentonites, alginic acid, pectin and sodium alginate are also specified.  The pH of the preparation should be between 4 and 7,5.  Examples of preparations are given.
OBJECTIVES: Patients with acute ischemic stroke (AIS) often have an accumulation of pre-existing comorbidities, but its clinical impact on outcomes after mechanical thrombectomy (MT) remains unknown. Therefore, we examined whether comorbidity burden before AIS onset could predict clinical outcomes after MT.
METHODS: In this retrospective cohort, we enrolled consecutive patients with community-onset AIS who underwent MT between April 2016 and December 2021. To evaluate each patient's comorbidity burden, we calculated Charlson comorbidity index (CCI), then classified the patients into the High CCI (≥ 3) and the Low CCI (< 3) groups. The primary outcome was a good neurological outcome at 90 days, defined as a modified Rankin scale 0-2 or no worse than the previous daily conditions. All-cause mortality at 90 days and hemorrhagic complications after MT were also compared between the two groups. We estimated the odds ratios and their confidence intervals using a multivariable logistic regression model.
RESULTS: A total of 388 patients were enrolled, of whom 86 (22.2%) were classified into the High CCI group. Patients in the High CCI group were less likely to achieve a good neurological outcome (adjusted odds ratio of 0.26 [95% confidence interval, 0.12-0.58]). Moreover, symptomatic intracranial hemorrhage was more common in the High CCI (14.0% vs. 4.6%; adjusted odds ratio, 4.10 [95% confidence interval, 1.62-10.3]).
CONCLUSIONS: Comorbidity burden assessed by CCI was associated with clinical outcomes after MT. CCI has the potential to become a simple and valuable tool for predicting neurological prognosis among patients with AIS and MT.
It was aimed to determine the immediate effect of myofascial release application on pain, flexibility and trunk mobility in chronic low back pain (CLBP). Forty patients with CLBP participated in this experimental study. Participants were grouped in randomized control. Visual Analogue Scale (VAS) was used for pain assessment. Sit-Reach Test for flexibility evaluation and Straight Leg Raising Test with goniometric measurement for hamstring flexibility were used. Modified Schober Test was applied to evaluate trunk mobility. Comparison of the pre- and post-treatment evaluation data of the individuals in the same group was made using the "Wilcoxen Sum Rank Test", one of the non-parametric tests. Comparison of pre- and post-treatment evaluation data of both groups was performed using the non-parametric evaluation "Mann-Whitney U Test".
PURPOSE: A composition for treating acute asthma caused by virus infection is provided to control increase of inflammation cell inside bronchoalveolar lavage fluid and airway resistance. CONSTITUTION: A composition for treating acute asthma caused by virus infection includes AS-605240 as an active ingredient. The acute asthma is induced by processing polyinosinic-polycytidylic acid. The AS-605240 suppresses expression of adhesion, inflammation cell, IgE, Th2, cytokine, chemokine, and vascular endothelial growth factor(VEGF). The composition is formulated in pharmaceutical unit dose form by adding pharmaceutically allowed carrier, excipient, or diluent. The composition is administered in effective amount of 0.1-1mg/kg. A health food for preventing or improving acute asthma caused by virus infection includes AS-605240 as an active ingredient.
The invention belongs to the technical field of medicinal and pharmaceutical compounds, and discloses a synthesis method and application of a histone deacetylase and microtubule dual-target inhibitor, wherein the left benzene ring of the molecular structural formula of the histone deacetylase and microtubule dual-target inhibitor is 3,4,5 trimethoxy substituted, the right benzene ring is disubstituted, R 2 The group is methoxyl, trifluoromethoxy and fluorine atom. Intermediate R 1 The substituent is hydrogen atom, methyl, nitrile group, nitro group or trifluoromethyl. All carbon and hydrogen atoms in the structure of all compounds contain various isotopes, the carbon atom containing C 12 ，C 14 The hydrogen atom includes H 1 ，H 2 And H 3 . The invention is different from single-target inhibitor and combined drug, has higher activity than single-target inhibitor, and can effectively inhibit cancerAnd (5) cell proliferation. Is safer than the combined medication. The strategy can be applied to the discovery of new antitumor drugs; the invention has strong killing ability to tumor cells and IC to some cells 50 Values are even on the pM scale.
A majority of military casualties occur during the pre-hospital period. The cause of death is largely associated with massive traumatic bleeding that leads to organ damage due to sustained hypoxia. Currently, therapeutics are lacking at the point of injury to mitigate hypoxic damage and maintain the survivability of severe hemorrhage prior to reaching medical facilities. This invention addresses that by introducing a method of co-administering prolyl hydroxylase domain inhibitor (PHDi, MK-8617), anti-fibrinolytic agent (tranexamic acid), and bradykinin receptor antagonist (icatibant) as anti-hemorrhage agents in combination with resuscitation fluid treatment with colloid solution of 25% human albumin that has an advantage of relatively small volume requirement to maintain blood volume. In addition, a kit comprising anti-hemorrhage agents that can be easily carried to the battlefield is also provided here. The therapeutic application of those agents on or near the point of injury can stabilize hypoxia inducible factor-1 alpha and enhance blood clot formation, which improves the patient's cellular adaptation to hypoxia and reduce hemorrhage, and thus can decrease organ failure and increase the patient's survivability.
Percutaneous cholecystostomy (PC) is often preferred over early cholecystectomy (EC) for elderly patients presenting with acute cholecystitis (AC). However, there is a lack of solid data on this issue. Following the PRISMA guidelines, we searched the Medline and Web of Science databases for reports published before December 2022. Studies that assessed elderly patients (aged 65 years and older) with AC treated using PC, in comparison with those treated with EC, were included. Outcomes analyzed were perioperative outcomes and readmissions. The literature search yielded 3279 records, from which 7 papers (1208 patients) met the inclusion criteria. No clinical trials were identified. Patients undergoing PC comprised a higher percentage of cases with ASA III or IV status (OR 3.49, 95%CI 1.59-7.69, p = 0.009) and individuals with moderate to severe AC (OR 1.78, 95%CI 1.00-3.16, p = 0.05). No significant differences were observed in terms of mortality and morbidity. However, patients in the PC groups exhibited a higher rate of readmissions (OR 3.77, 95%CI 2.35-6.05, p < 0.001) and a greater incidence of persistent or recurrent gallstone disease (OR 12.60, 95%CI 3.09-51.38, p < 0.001). Elderly patients selected for PC, displayed greater frailty and more severe AC, but did not exhibit increased post-interventional morbidity and mortality compared to those undergoing EC. Despite their inferior life expectancy, they still presented a greater likelihood of persistent or recurrent disease compared to the control group.
For blood assay validation and/or reproducibility testing, blood samples will be taken after an overnight fast or after oral glucose or a mixed meal and analyzed. Measurements will be made by: using different assays to determine best conditions of measurement, or repeat testing on different days. Endothelial cells will be collected from a 20-gauge intravenous catheter. One to six 0.025" J-wires will be sequentially inserted into the catheter. These measurements will allow us to determine: the reproducibility and variability of assays used, best timing of blood and endothelial cell collection and best blood volumes and endothelial cell collection wire passes to reliably perform routine assays. For imaging validation, algorithm development, and/or reproducibility testing, participants may undergo DEXA, MRI, or MRS testing to develop or improve analysis algorithms, to evaluate variability of the measurements, or testing different equipment that measure the same variable.
BACKGROUND/AIM: In the context of surgical de-escalation in early breast cancer (EBC), this study aimed to evaluate the contrast enhancement ultrasound (CEUS) sentinel lymph node (SLN) procedure as a non-invasive axillary staging procedure in EBC in comparison with standard SLN biopsy (SLNB).
PATIENTS AND METHODS: A subanalysis of the AX-CES study, a prospective single-arm, monocentric phase 3 study was performed (EudraCT: 2020-000393-20). The study included patients with EBC undergoing upfront surgery and SLN resection, with no prior history of locoregional treatment, and weighing between 40-85 kg. All patients underwent the CEUS SLN procedure as a non-invasive axillary staging procedure, with CEUS SLN accumulation marked using blue dye. After the CEUS SLN procedure, all patients underwent the standard mapping procedure. Data on success rate, systemic reactions, mean procedure time, mean surgical procedure, mean procedure without axillary staging, CEUS SLN appearance (normal/pathological), SLN number, and concordance with standard mapping procedure were collected.
RESULTS: After the CEUS SLN procedure, 29 LNs among 16 patients were identified and marked. In all cases, CEUS SLN revealed at least one LN enhancement. Six (37.50%) LNs were defined as pathological after the CEUS SLN procedure. Definitive staining of CEUS SLN pathology revealed metastatic involvement in four (66.67%) of the cases. Two SLNs were identified during the CEUS SLN procedure; however, owing to the low disease burden, no change in the surgical plan was reported.
CONCLUSION: The CEUS SLN procedure shows promise as a technique for non-invasive assessment of the axilla, potentially enabling safe axillary de-escalation in EBC by estimating the axillary disease burden.
Procedure to obtain new formulations based on lutein. The present invention describes a process for preparing microcrystalline lutein formulations, particularly in the form of esters, stable to oxidation and soluble in hydrophilic and/or lipophilic media. For them, the lutein esters are mixed with antioxidants, vegetable oils and/or organic solvents, this initial mixture being subjected to various stages depending on the type of formulation that is finally desired. These formulations are directly applicable as colorants in both the pharmaceutical, food and cosmetic fields. They can also be used as nutritional supplements. (Machine-translation by Google Translate, not legally binding)
The investigators will recruit appropriate patients, 120 in number, randomly allocate into control and experimental arms. They will be given GK#10 or placebo for 8 weeks. Clinical parameters, such as liver function, renal function, and general conditions will be evaluated at specific time points, week 0, 5, 9, and 13 weeks. Primary outcome measurement will be survival and major complications analysis, and secondary outcome measurement will be liver function evaluation.

The investigators anticipate providing our sponsor with useful results about GK#10. The investigators will make clear the impacts from individual strains, the investigators will validate our speculation that probiotics do no harm to cirrhotic patients with portal hypertension, even be beneficial to them. If the investigators can validate the anticipation, patients can enjoy benefits from our study, and the probiotics may have the potential to sell to the patients in the world.
The present invention relates to traditional Chinese medicine preparation for treating coronary disease and angina pectoris, and a preparation method for the traditional Chinese medicine preparation. The traditional Chinese medicine preparation is formed by extracting effective components of withered components of traditional Chinese medicine based on conventional process steps. Compared with the prior art, the medicine provided by the present invention has simple structure, so the production cost is low. Moreover, the quality can be better controlled. Moreover, the present invention has obvious therapeutic effects. The present invention has the main functions of warming properties, dispelling cold, regulating qi and alleviating pain. The present invention mainly treats diseases such as chest obstruction and cardiodynia (coronary disease and angina pectoris) caused by the loss of qi, chest and back pain, common cold and pain, chest distress, short breath, palmus, even asthma, unable prostration, pale complexion, peripheral coldness, white tongue coating and tight pulse.
To develop a clinical-radiomics nomogram based on spectral CT multi-parameter images for predicting lymph node metastasis in colorectal cancer. A total of 76 patients with colorectal cancer and 156 lymph nodes were included. The clinical data of the patients were collected, including gender, age, tumor location and size, preoperative tumor markers, etc. Three sets of conventional images in the arterial, venous, and delayed phases were obtained, and six sets of spectral images were reconstructed using the arterial phase spectral data, including virtual monoenergetic images (40 keV, 70 keV, 100 keV), iodine density maps, iodine no water maps, and virtual non-contrast images. Radiomics features of lymph nodes were extracted from the above images, respectively. Univariate analysis and least absolute shrinkage and selection operator (LASSO) regression were used to select features. A clinical model was constructed based on age and carcinoembryonic antigen (CEA) levels. The radiomics features selected were used to generate a composed radiomics signature (Com-RS). A nomogram was developed using age, CEA, and the Com-RS. The models' prediction efficiency, calibration, and clinical application value were evaluated by the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis, respectively. The nomogram outperforms the clinical model and the Com-RS (AUC = 0.879, 0.824). It is well calibrated and has great clinical application value. This study developed a clinical-radiomics nomogram based on spectral CT multi-parameter images, which can be used as an effective tool for preoperative personalized prediction of lymph node metastasis in colorectal cancer.